BackAbbvie Overview
Abbvie Inc

Abbvie Target Price

Analysts' average 12-month price target for Abbvie is $280.

Get informed when a big investor buys or sells

+ Follow

Share Price

$260.3

Average Target Price

$283.478.9% upside

19 analysts in the last 4 months

High: $303 | Low: $235

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-20Piper Sandler$30316.4% upsideOpen
2026-08-17Wells Fargo$30015.3% upsideOpen
2026-08-13Wolfe ResearchAlexandria Hammond$30015.3% upsideOpen
2026-08-04Guggenheim$28810.6% upsideOpen
2026-08-03Morgan Stanley$29613.7% upsideOpen
2026-08-03Canaccord GenuityGary Nachman$29011.4% upsideOpen
2026-07-29Barclays$30015.3% upsideOpen
2026-07-22Canaccord Genuity$2828.3% upsideOpen
2026-07-13UBS$2600.1% downsideOpen
2026-07-13BMO Capital$30015.3% upsideOpen
2026-07-10RBC CapitalTrung Huynh$2807.6% upsideOpen
2026-07-10Wells Fargo$29513.3% upsideOpen
2026-07-09Guggenheim$2610.3% upsideOpen
2026-07-06HSBC$30015.3% upsideOpen
2026-07-06Cantor Fitzgerald$2651.8% upsideOpen
2026-06-23Canaccord Genuity$2734.9% upsideOpen
2026-06-22Wells Fargo$2600.1% downsideOpen
2026-05-15Evercore ISI$2359.7% downsideOpen
2026-05-14Piper Sandler$29814.5% upsideOpen
2026-04-30Morgan Stanley$2786.8% upsideOpen
2026-04-23Piper Sandler$29412.9% upsideOpen
2026-04-20Canaccord Genuity$2620.7% upsideOpen
2026-04-10GuggenheimVamil Divan$2494.3% downsideOpen
2026-04-08Cantor Fitzgerald$2407.8% downsideOpen
2026-02-24RBC CapitalTrung Huynh$2600.1% downsideOpen
2026-02-19Barclays$2755.6% upsideOpen
2026-02-18Piper Sandler$29914.9% upsideOpen
2026-02-05UBS$23011.6% downsideOpen
2026-02-04Evercore ISIGavin Clark-Gartner$22812.4% downsideOpen
2026-01-28Goldman SachsAsad Haider$22314.3% downsideOpen
2026-01-20Berenberg Bank$2755.6% upsideOpen
2026-01-15BMO CapitalEvan David Seigerman$2580.9% downsideOpen
2026-01-07UBS$2407.8% downsideOpen
2025-12-12Morgan Stanley$2693.3% upsideOpen
2025-12-10HSBC$2651.8% upsideOpen
2025-11-05Piper SandlerDavid Amsellem$28911% upsideOpen
2025-11-03Raymond JamesGary Nachman$2561.7% downsideOpen
2025-10-20Guggenheim$2427% downsideOpen
2025-10-17Raymond JamesGary Nachman$2504% downsideOpen
2025-10-10Piper Sandler$2849.1% upsideOpen
2025-10-09Cantor Fitzgerald$2504% downsideOpen
2025-10-03UBS$2513.6% downsideOpen
2025-10-02HSBC$22513.6% downsideOpen
2025-09-15Cantor FitzgeraldCarter Gould$2455.9% downsideOpen
2025-02-03Raymond JamesGary Nachman$22015.5% downsideOpen
2025-02-03BMO CapitalEvan Seigerman$21517.4% downsideOpen
2024-11-12BMO CapitalEvan David Seigerman$20820.1% downsideOpen
2024-10-31BMO CapitalEvan David Seigerman$22812.4% downsideOpen
2024-10-31Bank of America SecuritiesCharlie Yang$21019.3% downsideOpen
2024-10-31CitigroupGeoff Meacham$22613.2% downsideOpen

Abbvie (ABBV) FAQ

As of the most recent data, ABBV shows a target price of $280. Scroll down for historical charts and peer comparison views.

If Abbvie moved to the average analyst target of $280, shares would be roughly 8.9% higher than $260.3. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Abbvie's earnings trajectory.

Besides this target price page, Stockcircle has Abbvie's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $280) with ownership activity and broader fundamentals.

Abbvie's target price is $280; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.